Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00385333 · ClinicalTrials.gov registry record · Phase 2
Metabolic Mapping to Measure Retinal Metabolism
A Phase 2 study, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00385333 is a Phase 2 study that has completed, run by National Eye Institute (NEI). The registered enrollment target is 28 participants.
The verdict
NCT00385333, a Phase 2 study, has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study will test whether a new non-invasive technique can quickly and precisely measure retinal metabolism (the amount of energy retinal cells use). The retina is the part of the eye that sends information to the brain. Participants in current NEI studies who have age-related macular degeneration (AMD), diabetic retinopathy, or von Hippel-Landau disease may be eligible for this study. Healthy volunteers will participate as controls. Patients with AMD must be 60 years of age or older; those with VHL disease or diabetic retinopathy must be 18 or older. Participants undergo the tests and procedures required in the NEI study in which they previously enrolled. In addition, for the current study, they undergo metabolic mapping. For this procedure, the subject's eyes are dilated, and different amounts of low-level light are shone into the eye to see how different cells respond with changes in metabolism. Measurements are taken while the subject breathes room air and while he or she breathes medical grade oxygen for about 1 minute. The entire procedure takes about 15 minutes.
Interventions
- PROCEDURE Feasibility Study - Imaging System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2006-09-29 |
| Est. Completion | 2010-09-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00385333
The ClinicalTrials.gov registry entry for NCT00385333 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Feasibility Study - Imaging System is the first listed.
NCT00385333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00385333 about?
NCT00385333 is a clinical study titled "Metabolic Mapping to Measure Retinal Metabolism". This study will test whether a new non-invasive technique can quickly and precisely measure retinal metabolism (the amount of energy retinal cells use). The retina is the part of the eye that sends information to the brain. Participants in current NEI studies who have age-related macular degenerati...
What is the current status of trial NCT00385333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2006-09-29. Estimated completion is 2010-09-16.
What interventions are being tested in trial NCT00385333?
The interventions under investigation include: Feasibility Study - Imaging System (PROCEDURE).
Who is sponsoring clinical trial NCT00385333?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.